TELA Bio (TELA) reported a Q4 net loss Thursday of $0.23 per diluted share, compared to a loss of $0.53 a year earlier.
One analyst polled by FactSet expected a loss of $0.24.
Revenue for the quarter ended Dec. 31 was $17.6 million, up from $17 million a year earlier.
Analysts polled by FactSet expected $23.2 million.
For Q1, the company has a revenue outlook of $17 million to $18 million. Four analysts expect $21 million.
The company expects full-year 2025 revenue between $85 million to $88 million. Analysts expect $93.8 million.
Shares fell 24% in recent after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。